A Pilot Study of Hemin Therapy for Gastroparesis (Diabetes Mellitus)

Mayo Clinic

Status and phase: Completed; Phase 2

Conditions: Gastroparesis; Diabetes Mellitus

Treatments: Biological: Albumin; Biological: Hemin

Study type: Interventional

Funder types: Other; Industry; NIH

Identifiers

NCT01206582

UL1TR000135 (U.S. NIH Grant/Contract)

09-000129

P01DK068055 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

This study is designed to learn if hemin can increase the production of heme oxygenase 1 and improve gastric (stomach) emptying and symptoms in diabetic patients with slow gastric emptying (gastroparesis).

Full description

Therapeutic options for management of diabetic gastroparesis are limited. Failure to maintain upregulation of heme oxygenase 1 (HO1) leads to loss of interstitial cells of Cajal and delayed gastric emptying in diabetic non-obese diabetic mice.

HO1 is an enzyme which protects cells from physical, chemical, and biologic stress. In mice with diabetes and slow gastric emptying, hemin increases HO-1 activity and improves gastric emptying. Hemin is produced from red blood cells and is approved by the Food and Drug Administration for treating acute porphyria, which is an inherited condition caused by an enzyme deficiency. Hemin is not approved by the Food and Drug Administration for treating gastroparesis.

In this study subjects were randomized to intravenous hemin, prepared in albumin, or albumin alone. After infusions on days 1, 3, and 7, weekly infusions were administered for 7 weeks. Assessments included blood tests for HO1 protein and enzyme activity levels, gastric emptying with 13^C-spirulina breath test, autonomic functions (baseline and end), and gastrointestinal symptoms every 2 weeks.

Enrollment: 20 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Where relevant (i.e., for ensuring safety), the inclusion and exclusion criteria are similar to those in a recently completed trial of hemin therapy for myelodysplastic syndrome at Rush University, Chicago (http://clinicaltrials.gov/ct2/show/NCT00467610).

• Upper gastrointestinal symptoms which satisfy criteria for postprandial distress syndrome or vomiting for the last 3 months with symptom onset at least 6 months prior to diagnosis
• At least moderately severe symptoms as manifest by a total symptom score of 2.5 or higher on the Gastroparesis Cardinal Symptom Index (GCSI)21
• Delayed gastric emptying (i.e, < 40% emptying at 2 and/or < 90% emptying at 4 hours by scintigraphy)
• No structural cause for symptoms by endoscopy within the past 12 months
• Patient must have a platelet counts > 50,000/microliters and absolute neutrophil counts (ANC) >500/microliters.
• Patient must have adequate hepatic and renal functions, defined as serum bilirubin, serum glutamic-oxaloacetic transaminase (SGOT), and serum glutamate pyruvate transaminase (SGPT) ≤ 2 times the upper limit of normal (ULN), and creatinine ≤ 1.5 times the ULN.
• Able to provide written informed consent before participating in the study

If female:

• Either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or if of childbearing potential, must comply with an effective method of birth control acceptable to the investigator during the study (oral contraceptives, Depo-Provera, intra-uterine device or barrier methods)
• Patient is not breastfeeding.
• Patient of childbearing potential must have a negative urine or serum pregnancy test during the screening period.

Exclusion criteria

• History of allergic reaction or significant sensitivity to Panhemantin ®
• Patients who have taken or used any investigational drug or device in the 30 days prior to screening
• Predominant symptoms of epigastric pain or rumination syndrome
• Structural cause for symptoms on recent endoscopy
• Patients with preexisting blood coagulation abnormalities
• Patients with previously documented renal impairment defined as above 150 mmol/L or 1.7 mg/dL serum creatinine
• Previous gastric or intestinal surgery - patients with enteral feeding tubes and/or venting/feeding gastrostomy will be eligible provided they can comply with study requirements. Tube feeding will be stopped 24 hours before the gastric emptying study
• Current use of narcotics, anticholinergic agents (e.g., hyoscyamine, belladonna), anticoagulants (e.g., warfarin) or erythromycin. Gastrointestinal prokinetic drugs (eg metoclopramide, or domperidone) may be continued at a stable dose throughout the study
• History of a pre-existing medical condition that, in the opinion of the investigator, will interfere with the participation in the study.
• History of venous thrombosis or hypercoagulable state
• Poor peripheral venous access, if central venous access is not available
• Uncontrolled active infection
• Any other condition or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for the study.
• Known intolerance or allergy to eggs
• Screening weight greater than 130 kg

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

20 participants in 2 patient groups, including a placebo group

Hemin

Active Comparator group

Description:

Panhematin®, Ovation Pharmaceuticals, Deerfield, Illinois (IL). Hemin was diluted in 25% albumin to obtain a concentration of 2.4 mg/mL and administered at a dose of 1.25 mL/Kg and at a rate of 60 mL/hour. 10 iv infusions for 8 weeks

Treatment:

Biological: Hemin

Albumin

Placebo Comparator group

Description:

10 iv infusions for 8 weeks

Treatment:

Biological: Albumin